CAPR Evp, General Counsel Karen Krasney Sells $12K of Stock
Karen Krasney, EVP and General Counsel of Capricor Therapeutics, sold 400 shares on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Karen Krasney, EVP, GENERAL COUNSEL at Capricor Therapeutics, Inc. ($CAPR), sold 400 shares at an average price of $30, worth about $12,000, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CAPR is down 21.8% after 1 week, down 33.2% after 1 month and down 77.3% to date (from the $29.51 close on Jun 24, 2026).
CAPR
Capricor Therapeutics, Inc.
Key Points
- Karen Krasney sold 400 shares of Capricor Therapeutics for $12,000 on June 24, 2026, at a price of $30 each.
- The stock closed at $29.51 on June 23, 2026, close to its 52-week high of $40.37, indicating a strong performance.
- Analysts generally recommend the stock as a 'buy', with a mean price target of $27 based on five analyst opinions.
Get $CAPR trade alerts by text
We text you when insiders, Congress or big funds trade $CAPR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Capricor Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Capricor Therapeutics, Inc.
Karen Krasney, the EVP and General Counsel of Capricor Therapeutics, Inc. (NASDAQ: CAPR), sold 400 shares on June 24, 2026, for a total of $12,000. The shares were sold at an average price of $30 each. This sale is part of a series of transactions involving insiders at the company.
Other Insider Activity
On June 25, 2026, Krasney also sold 24,100 shares, reflecting her active trading. CFO Anthony Bergmann has been involved in multiple transactions as well. On the same day as Krasney's sale, he bought 24,100 shares valued at approximately $76,638. Earlier, on June 22, he sold 24,100 shares, and a few days before that, he sold another 500 shares. These trades show a mix of buying and selling among the company's executives.
How Capricor Therapeutics, Inc. Stock Has Traded
Capricor Therapeutics shares are currently trading at $29.51, near their 52-week high of $40.37. The stock has seen significant movement recently, trading well above its 200-day moving average of $23.53. The company has a market capitalization of about $517.4 million. With the next earnings date set for November 10, 2026, investors will be looking for updates on its clinical trials and product developments.
Analysts Set New Price Targets
Analysts have been active in adjusting their ratings for Capricor. On September 14, 2026, B. Riley Securities upgraded the stock to a 'Buy' with a target price of $21. Piper Sandler also upgraded its rating to 'Overweight' with a target of $25 on September 1, 2026. However, there have been some downgrades as well, with firms like Jones Trading and Piper Sandler adjusting their ratings to 'Hold' and 'Neutral', respectively, in late July 2026.
What Capricor Therapeutics, Inc. Does
Capricor Therapeutics is a biotechnology company focused on developing advanced therapies for Duchenne muscular dystrophy and other serious diseases. Its lead product, Deramiocel, is currently in phase 3 clinical trials. The timing of Krasney's sale comes as the company prepares for its next earnings report.
What to Watch at Capricor Therapeutics, Inc.
Investors should keep an eye on Capricor's upcoming earnings report on November 10, 2026, which may provide insights into its clinical progress and financial health. The recent insider trades reflect past positions and may not indicate current strategies, as the 13F filings show historical data on holdings.
Related Filing Alerts
Source: Karen Krasney's Form 4 filing on $CAPR (Jun 24, 2026). Find the original filing: CAPR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts